4D Molecular Therapeutics Inc (FDMT) — Titan Protect Analysis

FDMT

4D Molecular Therapeutics Inc

Healthcare · ·

$8.64

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$502M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.58

Based on estimated future earnings — lower means cheaper

Rev Growth

+21,664.3%

Year-over-year revenue change

Profit Margin

-182.3%

How much profit the company keeps from each dollar of revenue

ROE

-34.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$29.00

+236% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 9 analysts covering this stock

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macu

https://www.4dmoleculartherapeutics.com

Country: United States Employees: 196 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

-0.107

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0258

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.436

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-39.6%

Historical annualised return based on price data

Max Drawdown

-90.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

115

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.76

Significantly more volatile than the market

52W High

$12.34

30% below the year high

52W Low

$3.68

135% above the year low

Avg Volume

739,187

Average daily shares traded — higher means easier to buy and sell

Short Ratio

18.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.57

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

4.55

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-145.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-2,416.2%

Profit from core operations before interest and tax

Free Cash Flow

$-69,357,248

Negative — the business is spending more than it generates

Revenue (TTM)

$88M

Total revenue over the last 12 months

Net Income

$-160,896,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$36.00

Target Median

$29.00

Target Low

$17.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go